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a b s t r a c t
Background: The monovalent oral rotavirus vaccine Rotarix was introduced into the UK infant
immunisation programme in 2013. We estimated vaccine effectiveness (VE) in the first two years of
the programme.
Methods: We used a test-negative case-control design and enhanced national surveillance data for 1869
vaccine-eligible children tested for rotavirus infection to obtain adjusted odds ratios and VE against
laboratory-confirmed rotavirus infections. Linked anonymised UK primary care and hospitalisation data
from the Clinical Practice Research Datalink (40,723 children) and random-effects Poisson regression
were used in a cohort study to estimate VE against all-cause acute gastroenteritis (AGE) and AGE
hospitalisations.
Results: VE against laboratory-confirmed infection was 69% (95% Confidence Interval: 40–84%) for one
dose and 77% (95%CI: 66–85%) for two doses. Two-dose VE in children aged <12 months and 12 months
was 85% (95%CI: 74–91%) and 54% (95%CI: 15–75%), respectively. In contrast, we found no evidence that
the vaccine was effective against all-cause AGE (VE = 20%, 95%CI: 36% to 5%), or against AGE
hospitalisations (VE = 35%, 95% CI: 86% to 77%).
Conclusions: In this first detailed assessment of VE of the Rotarix vaccine in the English national pro-
gramme, we show that Rotarix was highly effective in preventing laboratory-confirmed rotavirus infec-
tion in young children. This provides reassurance about the vaccine’s performance in real-life settings and
gives key information for future cost-effectiveness analyses. The high VE against rotavirus-specific AGE,
and the exceptionally successful implementation of the national rotavirus vaccine programme (with
>90% vaccine coverage), explains the lack of VE against all-cause AGE because most AGE in the post-
vaccine era would not have been due to rotavirus, although some underestimation of VE could also have
occurred due to differential healthcare utilisation by vaccinated and unvaccinated infants. This highlights
the importance of using specific vaccine-preventable endpoints for these scenarios.
 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Rotavirus is a major cause of severe acute gastroenteritis (AGE)
in young children in countries that have not introduced infant rota-
virus immunisation programmes [1]. Rotavirus group A is respon-
sible for >90% of human infections and virus genotypes are
classified by the virus glycoprotein (G-type) and protease-
sensitive protein (P-type), which can independently reassort. To
date, 15 G-genotypes and 28 P-genotypes have been described,
the most common genotype combinations circulating worldwide
being G1P[8], G2P[4], G3P[8], G4P[8], G9P[8] and G12P[8]. In
pre-licensure trials, the monovalent (G1P[8]) oral live-attenuated
rotavirus vaccine Rotarix (GlaxoSmithKline Biologicals, Rixensart,
Belgium) was shown to have >85% efficacy against severe
rotavirus-confirmed gastroenteritis in high- and middle-income
settings, and up to 40% efficacy against severe all-cause gastroen-
teritis [2]. In the UK Rotarix was introduced as a 2-dose schedule
at 2 and 3 months of age in July 2013. High national 2-dose vaccine
coverage of >90% by the age of 25 weeks was rapidly attained and
sustained [3,4].
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We have shown that, following vaccine introduction in England,
there was a substantial decline in hospital admissions for all-cause
AGE across all age groups and incident episodes of AGE presenting
to primary care, with reductions of 49% and 41% respectively
among infants during the rotavirus season [4,5]. We estimated that
these reductions were associated with a £12.5 million reduction in
healthcare costs for children aged <5 years in the first year of the
rotavirus immunisation programme [5].
Although these ecological studies provide strong evidence of
the impact of the rotavirus immunisation programme, it is impor-
tant to extend the analyses to individual-level data to allow direct
assessment of rotavirus vaccine effectiveness (VE) in the public
health setting. We therefore investigated the direct effect of the
monovalent rotavirus vaccine against two different endpoints dur-
ing the first two years of the programme in England. The first anal-
ysis involved a test-negative case-control design using enhanced
laboratory surveillance data to estimate VE against laboratory-
confirmed rotavirus infections. The second was a cohort study,
using large linked electronic health datasets to estimate VE against
all-cause AGE, and severe all-cause AGE resulting in
hospitalisation.
2. Methods
2.1. Vaccine effectiveness against rotavirus-confirmed AGE
Rotavirus-positive stool specimens were obtained from
enhanced national surveillance for rotavirus gastroenteritis, set
up following introduction of Rotarix into the infant immunisation
programme in England. Briefly, NHS hospital laboratories in Eng-
land and Wales routinely report rotavirus-positive infections elec-
tronically to Public Health England (PHE) as part of national
infection surveillance. Detection methods vary between hospital
sites and may have been performed by antigen detection assays
or nucleic acid amplification tests. PHE actively followed up all
positive reports in vaccine-eligible infants (born on/after 01 May
2013 and aged6 weeks at diagnosis). Reporting laboratories were
asked to submit stool specimens in which rotavirus (antigen or
RNA) was identified by any method to the national Virus Reference
Department (VRD) for confirmation of the rotavirus diagnosis by
reverse-transcription real-time PCR [6,7]. Specimens in which rota-
virus RNA was detected at a cycle threshold (Ct) value of 35 were
considered rotavirus-positive and were eligible for molecular char-
acterisation. These rotavirus-positive specimens were further anal-
ysed to determine rotavirus genotypes according to established
binomial classification using the virus VP4 (P) and VP7 (G)
sequences (as GxP[x]) [8]. All G1P[8] type viruses were further dif-
ferentiated as wild-type and vaccine-derived. G1P[8] Rotarix
vaccine-derived strains were defined either where sequences of
VP4 and VP7 demonstrated highest homology with Rotarix
sequences (accession numbers JX943612 and JX943614, respec-
tively); and/or through detection of Rotarix sequence directly
using a previously published and validated qRT-PCR assay that
specifically targets the NSP2 gene of the Rotarix strain [9]. Con-
trols (infants with rotavirus-negative gastroenteritis) were
obtained via eight sentinel NHS hospital laboratories across Eng-
land. These laboratories reported results for all patients who had
been tested for rotavirus, irrespective of the final test result, with
information on the patient’s age and sex [10].
In the second surveillance year (July 2014–June 2015), because
of the large number of rotavirus-negative results relative to
rotavirus-positive results in vaccine-eligible children, we fre-
quency matched on age (10–24 weeks, 25–52 weeks and
>52 weeks) and on month of onset to select approximately 10%
of the large pool of potential controls. This was to achieve a similar
number of controls as wild type rotavirus-confirmed cases. Vacci-
nation status and details of the illness for cases and controls were
obtained from their general practitioner using a standardised
questionnaire.
2.1.1. Analysis
All data were entered into a custom Access database and anon-
ymised before analysis. Children for whom the sample was taken
28 days after the date of onset of illness were excluded from
analyses, due to concerns about misclassification of rotavirus sta-
tus. We also restricted analyses to children who were 10 weeks
of age, to allow at least two weeks after the first vaccine dose. Sam-
ples with an onset date that was missing or was later than the sam-
ple date were reassigned with an onset date of four days prior to
the sample date, based on the median value of this difference in
the remaining samples. Logistic regression was then used to esti-
mate adjusted odds ratios (aOR) for vaccination, adjusting for age
in months and the month and year of symptom onset. Episodes
of illness that occurred during the two weeks after each dose of
vaccine were analysed separately. VE was calculated as (1-aOR).
Analyses were conducted initially using all rotavirus-positive
cases, and then repeated after excluding rotavirus-positive cases
that were subsequently identified as vaccine-derived rotavirus
strains or that could not be confirmed on re-analysis by the VRD.
Further analyses were conducted to investigate waning of VE by
repeating analyses for infants aged younger than and older than
twelve months of age. In sensitivity analyses, we estimated VE
after substituting the reported date of AGE onset with the date
the sample was taken.
2.2. Vaccine effectiveness against all-cause acute gastroenteritis
This analysis utilised anonymised primary care data from the
Clinical Practice Research Datalink (CPRD), which comprises a rep-
resentative sample of approximately 7% of the UK population [11].
Data include clinical, prescription, vaccination and lifestyle data,
referrals to and feedback from secondary care. The data were pro-
vided pre-linked at an individual level to data on hospitalisations
(Hospital Episode Statistics) and on social deprivation (index of
multiple deprivation) [12].
We included infants born after April 2013 who were registered
within six weeks of age with a CPRD practice in England that had
reached established quality standards and had consented to link-
age of patients’ general practice records to hospitalisation data.
The subset of infants who had a recorded AGE event in their linked
electronic health records during the follow-up period were eligible
for AGE severity (hospitalisation) analyses.
The primary outcome of interest was incident AGE, diagnosed in
general practice or in hospital. Most AGE in general practice is
diagnosed clinically without laboratory confirmation of the causa-
tive pathogen, and most hospitalised AGE is not coded using
pathogen-specific codes. We therefore used a broad definition of
AGE, as described in our previous ecological study [5]. Briefly, we
identified AGE diagnoses using Read codes in general practice data,
and ICD10 codes in the primary or secondary diagnostic fields in
the hospitalisation data, with each code categorised into one of
four AGE subtypes, namely infectious gastroenteritis, non-
infectious gastroenteritis of specified cause, non-infectious gas-
troenteritis of unspecified cause and gastroenteritis of unspecified
type; all codes and their subtype categorisation are provided in the
Supplementary data. We assumed that AGE consultations/hospitali
sations within 28 days of each other were part of the same episode.
The first consultation within an episode was recorded as the inci-
dent date of that episode. The type of AGE episode was defined
using the constituent Read or ICD10 codes. We excluded episodes
of non-infectious AGE of specified cause from further analyses but
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included non-infectious AGE of unspecified cause, as previous
studies have shown that this is often miscoded infectious AGE [5].
The secondary outcome was severe AGE, defined as a hospital-
isation for AGE within 28 days of an incident AGE event. The subset
of infants whose AGE diagnosis was made in hospital (bypassing
the GP) were included in severity analyses and were all considered
to have the outcome of interest (an AGE hospitalisation).
Rotavirus vaccination status was identified using recorded
information in the infants’ immunisation files in the general prac-
tice data, supplemented by Read and prescription codes in the clin-
ical and therapy files (for code lists, see the Appendix). Vaccination
status was considered as a time-varying exposure and we
subdivided infants’ person-time into: unvaccinated (Group 0);
0–2 weeks after the first vaccine dose (Group 1); >2 weeks after
the first vaccine dose and before receipt of the second dose (Group
2); 0–2 weeks after the second vaccine dose (Group 3); and
>2 weeks after the second vaccine dose (Group 4). We considered
Group 0 as unvaccinated, Group 2 as having had 1 dose and Group
4 as having had both doses. The two-week windows after each
dose (Groups 1 and 3) were considered as ‘‘partially vaccinated”
(for 1st or 2nd dose) and the person-time was considered
separately in analyses.
Covariates of interest included age, index of multiple depriva-
tion (at the individual level when available, otherwise at the gen-
eral practice level), geographical region, calendar year, calendar
month and rotavirus season. The latter was based on historical pat-
terns of rotavirus activity and categorised into low (July-
September), medium (October-January and May) and high
(February-April) activity [13]. We also examined the effect of
whether the infant had been a preterm birth, obtaining this infor-
mation from the subset of infants that were included in the
recently available CPRD/LSHTM Pregnancy Register [14].
2.2.1. Analysis
In primary analyses of incident AGE, the start of follow-up for
each infant was at six weeks of age; the end of follow up was the
earliest of the date the infant left the practice, died or reached
one year of age, the date that the practice last contributed data
to CPRD, and 30th September 2015. In AGE hospitalisation analy-
ses, the start of follow-up was the AGE incident date, and the
end of follow up was determined as for the primary analyses with
the additional criterion of 28 days after the AGE diagnosis.
Incidence of AGE, and of an AGE hospitalisation after AGE, were
calculated in a random-effects Poisson model (to allow for multiple
events per individual), for vaccinated (one- and two- dose) and
unvaccinated infants, adjusted for age in months, IMD, calendar
month, calendar year, geographical region and pre-term birth sta-
tus. The adjusted incidence rate ratio (aIRR) was used to calculate
VE (1-aIRR). We expected that VE against all-cause AGE would be
higher during periods of higher rotavirus circulation, when most
AGE in infants would be due to rotavirus. Thus, in further analyses,
VE was calculated against AGE diagnosed during the high-activity
rotavirus period.
Data from both studies were analysed using Stata MP v.14.1
(StataCorp, College Station, TX)
2.3. Ethics approval
For the laboratory data study, PHE has legal permission, pro-
vided by Regulation 3 of The Health Service (Control of Patient
Information) Regulations 2002, to process patient confidential
information for national surveillance of communicable diseases
[15]. This includes PHE’s responsibility to monitor the safety and
effectiveness of vaccines. Approval for the all-cause AGE study
was obtained from the Observational Research Ethics Committee
of the London School of Hygiene and Tropical Medicine
(reference:11843) and from the Independent Scientific Advisory
Committee (ISAC) of the Medicines and Healthcare products Regu-
latory Agency (reference:16_048). The ISAC protocol was made
available to the reviewers of this paper.
3. Results
3.1. VE against laboratory-confirmed rotavirus infection
In total, 2414 rotavirus-positive test reports (potential cases)
were submitted by local laboratories during the two-year surveil-
lance period, 733 with onset of illness in 2013/14 and 1681 with
onset in 2014/15 (Fig. 1). 545 of these potential cases were
excluded either because the patient was aged <10 weeks, because
the sample was taken >28 days after symptom onset or because
of missing or conflicting data. The sentinel laboratories provided
3489 rotavirus-negative test results, from which 1116 were
selected as controls. Vaccination status was obtained for all 1869
cases, and for 1032 (92%) controls (763 in 2013/14, and 269 in
2014/15, Fig. 1).
Cases were similar in age to controls in both the first surveil-
lance year (median age of cases versus controls: 19.4 weeks (range:
10.0–58.1 weeks) versus 20.4 weeks (range: 10.0–50.7 weeks)) and
in the second year (median age 50 weeks (10.0–110.7 weeks) vs
54.7 weeks (10.4–108.0 weeks)). Cases and controls were also sim-
ilar with respect to sex in both years (cases: 53.7% male versus con-
trols: 53.5% male), and in the timing of specimen collection (5.9% of
cases vs. 5.4% of controls had a gap of >14 days between specimen
collection and testing). Among those with available information,
42% of cases (425/1017) and 45% of controls (158/349) were hospi-
talised. After adjusting for age and for the month and year of illness
onset, the estimated VE was modest, at 20% (95% CI: 14% to 43%)
for one dose and 40% (23–53%) for two doses (Table 1a).
From the 1869 rotavirus positive cases used in the initial anal-
ysis, 862 stool specimens were submitted to the reference labora-
tory for confirmation of the rotavirus diagnosis and strain typing. A
total of 310 (36%) specimens were not confirmed as rotavirus pos-
itive and were excluded (Fig. 1). A further 106 specimens were
determined to contain vaccine-derived rotavirus strains (n = 98)
or had results that were undetermined or unavailable (n = 8). The
commonest wild-type rotavirus genotypes detected in the remain-
ing 446 specimens were G1P[8] (n = 50), G2P[4] (n = 106) and
G12P[8] (n = 113). VE was appreciably higher when cases were
restricted to those with confirmed wild-type infection, at 69%
(95% CI:40–84%) for one dose and 77% (95% CI:66–85%) for two
doses (Table 1b).
When data were stratified by the age of the child, there was evi-
dence that VE was higher in children aged <12 months for the anal-
ysis restricted to confirmed cases, at 85% (95% CI:74–91%)
compared to 54% (95% CI:15–75%) for children aged 12 months
(Table 2).
When analyses were repeated using the sample date instead of
the reported AGE onset date, results were broadly similar, with
two-dose VE against confirmed infection of 72% (95% CI: 59–81%,
data not shown). We also carried out a post-hoc analysis, restricted
to cases and controls who had specimens tested 14 days after
symptom onset: VE estimates were very similar to those derived
from all cases and controls (Supplementary Table 1).
3.2. VE against all-cause AGE
In total, 40,723 eligible infants were included in the all-cause
AGE analysis. Vaccine coverage was high, with 88% receiving one
dose and 79% receiving two doses of vaccine.
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Over the two-year study period, 4742 infants had 1AGE
episode (4266 infants had one episode, 438 had two episodes, 34
had three episodes and 4 had four episodes), of which 4845
episodes occurred outside the two weeks after vaccination. Rates
of all-cause AGE during non-vaccinated periods, and after receipt
of one dose and two doses of vaccine were 160.1, 167.2 and
Fig. 1. Flow chart of results of rotavirus testing of infants (01/07/2013-30/06/2015).
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228.6 cases/1000 person-years respectively (Table 3). After adjust-
ing for age, deprivation, month and year, there was no evidence
that the vaccine protected against all-cause AGE, with effectiveness
of 0% (95% CI: 16 to 13%) for one dose and 20% (95% CI: 36 to
5%) for two doses. Further adjustment for geographical region
made little difference to the results (data not shown). Only 166
AGE episodes (3.4%) among 164 infants resulted in hospitalisation.
Although the point estimates for VE against hospitalised AGE were
greater than zero, with a 47% and 35% reduction in AGE hospitali-
sations after one and two doses respectively, 95% confidence inter-
vals were wide and included the null value (Table 3).
Similar results were found after stratifying by year, and after
restricting to AGE in high rotavirus season (Supplementary
Table 2). Among the subset of 34,561 infants who were included
Table 1
Rotavirus vaccine effectiveness against rotavirus infection.
Vaccine dose Cases Controls Adjusted ORa (95% CI) Vaccine effectiveness (95% CI)
(a) All cases
0 390 173 Ref Ref
1 186 130 0.80 (0.57, 1.14) 20% (14%, 43%)
2 1126 653 0.60 (0.47, 0.77) 40% (23%, 53%)
TOTAL 1702b 956b
(b) Virus Reference Department confirmed wild-type cases
0 133 173 Ref Ref
1 26 130 0.31 (0.16, 0.60) 69% (40%, 84%)
2 277 653 0.23 (0.15, 0.34) 77% (66%, 85%)
TOTAL 436c 956b
a Odds ratio, adjusted for age in months, month of onset of AGE and year of onset of AGE.
b Data not shown for 167 cases and 76 controls with AGE onset in the 2 weeks after rotavirus vaccination.
c Data not shown for 10 cases with AGE onset in the 2 weeks after rotavirus vaccination.
Table 2
Rotavirus vaccine effectiveness against rotavirus infection, stratified by age at onset of illness.
Vaccine dose Cases Controls Adjusted ORa (95% CI) Vaccine effectiveness (95% CI)
(a) Age <12 months: All cases
0 255 155 ref ref
1 153 125 0.81 (0.56, 1.17) 19% (-17%, 44%)
2 624 524 0.62 (0.47, 0.83) 38% (17%, 53%)
TOTAL 1032b 804b
(b) Age <12 months: Virus Reference Lab confirmed wild-type cases
0 79 155 ref ref
1 14 125 0.20 (0.09, 0.46) 80% (54%, 91%)
2 91 524 0.15 (0.09, 0.26) 85% (74%, 91%)
TOTAL 184c 804b
(c) Age 12 months: All cases
0 135 18 ref ref
1 33 5 0.92 (0.31, 2.72) 8% (172%, 69%)
2 502 129 0.54 (0.31, 0.93) 46% (7%, 69%)
TOTAL 670 152d
(d) Age 12 months: Virus Reference Department confirmed wild-type cases
0 54 18 ref ref
1 12 5 0.81 (0.23, 2.86) 19% (186%, 77%)
2 186 129 0.46 (0.25, 0.85) 54% (15%, 75%)
TOTAL 252e 152d
a Odds ratio, adjusted for age in months, month of onset of AGE and year of onset of AGE.
b Data not shown for 166 cases and 75 controls with AGE onset in the 2 weeks after rotavirus vaccination.
c Data not shown for 10 cases with AGE onset in the 2 weeks after rotavirus vaccination.
d Data not shown for 1 control with AGE onset in the 2 weeks after rotavirus vaccination.
e No case had AGE onset in the 2 weeks after rotavirus vaccination.
Table 3
Rotavirus vaccine effectiveness against (a) all-cause acute gastroenteritis (AGE), and (b) hospitalisation after AGE.
Vaccine dose Person-years AGE cases Rate/1000py Adjusted RRa(95% CI) Vaccine effectiveness (95% CI)
(a) Against any AGE
0 3534 566 160.1 Ref Ref
1 2701 452 167.2 1.00 (0.87, 1.16) 0 (16, 13)
2 16,733 3827 228.6 1.20 (1.05, 1.36) 20 (36, 5)
TOTAL 22,968 4845
(b) Against hospitalised AGE Hospitalisations
0 95.2 26 272.9 ref ref
1 114.7 17 147.13 0.53 (0.19, 1.45) 47 (-45, 81)
2 1533.7 106 69.07 0.65 (0.23, 1.86) 35 (86, 77)
TOTAL 1743.6 149
a Incidence rate ratio, adjusted for age, deprivation, month of onset of AGE and year of onset of AGE.
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in the CPRD pregnancy register, additional adjustment for prema-
turity gave an estimated effectiveness against all-cause AGE of
0% (95% CI: 15 to 26%) for one dose, and 18% (95% CI: 36 to
2%) for 2 doses.
After seeing these results, we considered whether health-
seeking behaviour might have resulted in increased AGE ascertain-
ment among vaccinated infants, resulting in underestimation of
VE. We therefore carried out a further analysis, restricting to
infants who had at least one other general practice consultation
after four months of age. In this revised analysis, there remained
no evidence of effectiveness against all-cause AGE (effectiveness
for one dose: 3% (95% CI: 12 to 16%); for two doses: 17% (95%
CI: 33 to 3%)
4. Discussion
In these two studies of a highly vaccinated infant population, a
strong protective effect of Rotarix was demonstrated against
laboratory-confirmed rotavirus infection in the first two years of
the programme; estimated effectiveness was 77% overall, and
>80% in infants in their first year of vaccine receipt. In contrast,
we did not demonstrate VE against all-cause AGE; as discussed
below, this is likely to be due to the successful implementation
of the vaccination programme, with high and sustained vaccine
coverage and a substantial impact of the vaccine.
Inclusion of all cases initially classified as rotavirus-positive by
local laboratories led to lower VE, and demonstrates the impor-
tance of confirming rotavirus diagnoses and strain characterisa-
tion, particularly to distinguish wild-type infection from excreted
vaccine. Methods employed for primary detection of rotavirus
infection across frontline diagnostic laboratories differs from site-
to-site. Whilst there is a general trend to move toward molecular
assays, some laboratories continue to utilise immunochromato-
graphic methods which can have low diagnostic specificity com-
pared to enzyme immnoassays and nucleic acid detection [16].
Laboratory methods for detection of rotavirus RNA based on PCR
approaches are highly sensitive and can detect the presence of viral
RNA in both clinical and subclinical infection. Studies have
attempted to identify Ct cutoff values which discriminate clinical
from subclinical infection, for which Ct values around Ct 24–27
have been recommended [17,18]. In this study, we selected a
higher Ct cutoff of 35 because alongside confirming rotavirus infec-
tion associated with clinical disease, we were interested to monitor
where G1P[8] Rotarix-vaccine-derived viruses were being
detected in infants, and we anticipated that RNA levels in such
specimens would be low and hence associated with Ct values
>27. It is likely that among cases in whom vaccine-derived virus
was detected, AGE was caused by other pathogens or non-
infectious aetiologies in recently rotavirus-vaccinated children,
with the vaccine strain found coincidently (thus misclassifying
cases). Clinicians managing infants in primary and secondary care
need to be aware that infants vaccinated with the oral rotavirus
vaccine may secrete the vaccine strain in their stools for up to three
weeks after vaccination; submitting stool samples for rotavirus
testing during this period may, therefore, lead to a misdiagnosis
of rotavirus gastroenteritis. Whilst the attenuated vaccine strain
may cause mild symptoms including diarrhoea in some immunised
infants, other causes need to be considered in unwell infants with
more severe symptoms. Nearly all vaccine-derived strains are
identified in 2- and 3-month old infants (i.e. when they are due
the oral rotavirus vaccine) and do not constitute vaccine failure,
unless the strain is confirmed by the reference laboratory as
wild-type, which is now rare in the UK in this age group in partic-
ular. The increasing use of molecular testing by local laboratories
highlights the importance of referral of specimens for differentiating
wild-type rotavirus infections from vaccine derived strains, and
continued work to establish cut offs to distinguish clinically rele-
vant infections.
Our estimated VE against laboratory-confirmed rotavirus infec-
tion is consistent with findings from pre-licensure trials in high-
income settings and with other European post-licensure studies
of vaccine-eligible age groups (estimating the direct effect of vac-
cination); the latter have reported effectiveness against healthcare
visits for rotavirus-related illness ranging from 68 to 98% [2,19].
Evidence of waning VE of the monovalent vaccine over the first
2–3 years of life has been inconsistent. A recent systematic review
reported evidence of similar effectiveness among children aged
<12 months versus >12 months in low-mortality settings, but
lower effectiveness in the second year of life in studies from
medium- and high-mortality settings [20]. However, a study in
Germany, where both the monovalent and pentavalent rotavirus
vaccines are available, reported lower VE against outpatient visits
for rotavirus diarrhoea among children aged 18–29 months com-
pared to children aged 6–17 months (57% vs 74% respectively) [21].
Our findings of no VE against all-cause AGE is in contrast to the
results of our previous vaccine impact studies, which showed
marked reductions in all-cause AGE at the population level across
healthcare settings after rotavirus vaccine introduction, for infants
and for older children not targeted for vaccination [4,5]. Other
studies of the monovalent vaccine in populations with appreciably
lower vaccination coverage than in the UK have found higher VE
against AGE [22]. For example, in Israeli infants, VE against AGE
healthcare consultations was 50.1% (95% CI:47.5–52.6%), and in
Australian children aged <60 months, effectiveness against AGE
hospitalisations was 77.7% (95% CI:40.2–91.7%) [23,24]. Con-
versely, there was no evidence of effectiveness against community
cases of AGE in a study of Brazilian infants with high vaccine
uptake, with similar incidence of AGE in unvaccinated and unvac-
cinated children [25].
The divergent findings of a strong impact of rotavirus vaccine
against all-cause AGE but little evidence of VE is likely to be due
to the highly effective implementation of the vaccination pro-
gamme, with rapid attainment of >90% vaccine coverage by
25 weeks of age, together with high VE against rotavirus-specific
AGE [3,4]. As a result, almost all AGE in the study population in
the post-vaccine era was likely to have been due to non-
rotavirus organisms (or non-infectious causes). This also explains
the higher VE against all-cause AGE found in previous studies of
rotavirus in populations with lower vaccine coverage, in which
there would have been more circulating rotavirus among infants
compared to our study population.
Our two studies have several strengths. Both were population-
based with results that should be generalizable to the UK popula-
tion, and the cohort study was large. We used detailed diagnostic
algorithms to identify episodes of all-cause AGE, and multivariable
analyses to adjust for important potential confounders. Samples in
the laboratory-based study underwent additional testing to con-
firm or refute rotavirus diagnoses and, importantly, to exclude
cases with positive rotavirus results due to detection of excreted
vaccine virus rather than wild-type rotavirus infection. Also, local
laboratory staff were unaware of the vaccination status of the chil-
dren tested for rotavirus, minimising the risk of bias arising from
preferential sending of samples to Public Health England.
Some limitations also need consideration. There were relatively
small numbers of laboratory-confirmed cases, due to the effective-
ness of the vaccine and high vaccine coverage, resulting in rela-
tively wide confidence intervals for some estimates. The limited
number of confirmed cases also prevented separate assessment
of VE against homotypic and heterotypic rotavirus strains,
although the high effectiveness estimate obtained is consistent
with strong cross-protection against non-G1P[8] rotavirus strains
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shown in the pre-licensure trials [26,27]. Information on geograph-
ical region and on socio-economic status was not available in the
laboratory dataset, and so these variables were not adjusted for
in the test negative analysis. However, national rotavirus vaccine
coverage data indicate that there is little variation in vaccine
uptake regionally [28]. Furthermore, the cases and controls in the
test negative study all had AGE, had sought healthcare, and from
the available evidence appear to have had similar severity of ill-
ness. Thus, socioeconomic status should not have been a major
confounder of the rotavirus-confirmed VE estimate; cases and con-
trols are also likely to have been similar with respect to other risk
factors for an acute gastrointestinal illness. Not all general prac-
tices responded to the request for vaccination data for the controls
in the second year of the study, but response rates were 100% for
cases (in both study years) and for controls in the first year, and
we have no reason to believe that infants from non-responding
practices had different vaccine uptake to those that responded.
Similarly, it seems unlikely that GPs would under-report vaccina-
tion history in cases or controls – if any under-reporting did occur
it would most likely be random with respect to case/control status,
which would result in a (probable small) underestimation of VE.
It is possible that some of the apparent lack of effect of vaccina-
tion against all-cause AGE (and the slight protective effect seen for
two doses) was due to health-seeking behaviour among parents of
vaccinated children. However, estimates were very similar when
analyses were restricted to infants that were being brought to
the GP for other reasons, and health-seeking behaviour is unlikely
to explain the lack of effectiveness against severe AGE resulting in
hospitalisation. Nevertheless, some underestimation of VE against
all-cause AGE could have occurred as a result of differential health-
care utilisation by vaccinated and unvaccinated infants. A recent
UK study applied novel methods to estimate propensity for vaccine
uptake in a primary care birth cohort of infants and applied this to
estimate rotavirus VE against all-cause AGE seen in general prac-
tice [29]. After adjusting for propensity to be vaccinated, the direct
effectiveness of rotavirus vaccine shifted from a negative value
(VE = 26%, 95%CI: 48%, 7%) to no clear evidence of effective-
ness (VE = 11%, 95%CI: 11%, 29%); when further restricted to rota-
virus season (defined as January-May), the propensity-adjusted
direct VE was positive, although with very wide confidence inter-
vals (VE = 26%, 95%CI = 1%, 45%). A strength of the test-negative
design is that the caregivers of all the children (cases and controls)
sought care for their child, and thus if a control had developed
rotavirus infection they would have been likely to be included as
a case.
In conclusion, we have demonstrated high effectiveness of
monovalent rotavirus vaccine against rotavirus-confirmed infec-
tions in the first two years of the programme. This provides reas-
surance that the vaccine is effective in routine use in England,
and provides key information for future cost effectiveness analyses,
helping to ensure the financial sustainability of the rotavirus vacci-
nation programme. As data accumulate in the post-vaccination era,
more detailed assessment of waning of effectiveness over time can
be undertaken, and investigation of rotavirus strain-specific pro-
tection. Our study also highlights the key importance of using
specific outcomes when vaccine coverage and vaccine effective-
ness are both very high.
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